AstraZeneca Plc will invest $15 billion in China through 2030 to expand medicines and manufacturing and research and development, in a further commitment to the UK drugmaker’s already sizeable presence in the mainland.
The UK drugmaker — whose Chief Executive Officer Pascal Soriot is currently visiting China as part of UK Prime Minister Keir Starmer’s official visit — said the investment will help it leverage the mainland’s scientific excellence and advanced manufacturing to deliver “cutting-edge treatments to patients across China and globally.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.